Compare RNGR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | NGNE |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.7M | 327.8M |
| IPO Year | 2017 | 2014 |
| Metric | RNGR | NGNE |
|---|---|---|
| Price | $17.05 | $19.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $17.00 | ★ $57.63 |
| AVG Volume (30 Days) | ★ 190.2K | 116.6K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.17 | N/A |
| Revenue Next Year | $5.95 | N/A |
| P/E Ratio | $31.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.56 | $10.46 |
| 52 Week High | $17.98 | $37.27 |
| Indicator | RNGR | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 43.35 |
| Support Level | $16.25 | $15.96 |
| Resistance Level | $17.25 | $21.03 |
| Average True Range (ATR) | 0.53 | 1.73 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 42.13 | 7.07 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.